Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1626gms

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

| | | | |
|---|---|---|---|
| NEWS | 1 | | Web Page URLs for STN Seminar Schedule - N. America |
| NEWS | 2 | | "Ask CAS" for self-help around the clock |
| NEWS | 3 | SEP 09 | CA/CAplus records now contain indexing from 1907 to the present |
| NEWS | 4 | DEC 08 | INPADOC: Legal Status data reloaded |
| NEWS | 5 | SEP 29 | DISSABS now available on STN |
| NEWS | 6 | OCT 10 | PCTFULL: Two new display fields added |
| NEWS | 7 | OCT 21 | BIOSIS file reloaded and enhanced |
| NEWS | 8 | OCT 28 | BIOSIS file segment of TOXCENTER reloaded and enhanced |
| NEWS | 9 | NOV 24 | MSDS-CCOHS file reloaded |
| NEWS | 10 | DEC 08 | CABA reloaded with left truncation |
| NEWS | 11 | DEC 08 | IMS file names changed |
| NEWS | 12 | DEC 09 | Experimental property data collected by CAS now available in REGISTRY |
| NEWS | 13 | DEC 09 | STN Entry Date available for display in REGISTRY and CA/CAplus |
| NEWS | 14 | DEC 17 | DGENE: Two new display fields added |
| NEWS | 15 | DEC 18 | BIOTECHNO no longer updated |
| NEWS | 16 | DEC 19 | CROPU no longer updated; subscriber discount no longer available |
| NEWS | 17 | DEC 22 | Additional INPI reactions and pre-1907 documents added to CAS databases |
| NEWS | 18 | DEC 22 | IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields |
| NEWS | 19 | DEC 22 | ABI-INFORM now available on STN |
| NEWS | 20 | JAN 27 | Source of Registration (SR) information in REGISTRY updated and searchable |
| NEWS | 21 | JAN 27 | A new search aid, the Company Name Thesaurus, available in CA/CAplus |
| NEWS | 22 | FEB 05 | German (DE) application and patent publication number format changes |

| | |
|---|---|
| NEWS EXPRESS | DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003 |
| NEWS HOURS | STN Operating Hours Plus Help Desk Availability |
| NEWS INTER | General Internet Information |
| NEWS LOGIN | Welcome Banner and News Items |
| NEWS PHONE | Direct Dial and Telecommunication Network Access to STN |
| NEWS WWW | CAS World Wide Web Site (general information) |

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:12:30 ON 27 FEB 2004

=> FIL CAPLUS

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 0.21 | 0.21 |

FILE 'CAPLUS' ENTERED AT 12:12:38 ON 27 FEB 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.


FILE COVERS 1907 - 27 Feb 2004 VOL 140 ISS 10
FILE LAST UPDATED: 26 Feb 2004 (20040226/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s epothilone?
L1          607 EPOTHILONE?

=> s l1 and epothilone(w)A
            548 EPOTHILONE
            325 EPOTHILONES
            607 EPOTHILONE
                  (EPOTHILONE OR EPOTHILONES)
       17684704 A
            294 EPOTHILONE(W)A
L2          294 L1 AND EPOTHILONE(W)A

=> s l1 and epothilone(w)B
            548 EPOTHILONE
            325 EPOTHILONES
            607 EPOTHILONE
                  (EPOTHILONE OR EPOTHILONES)
        1410193 B
            300 EPOTHILONE(W)B
L3          300 L1 AND EPOTHILONE(W)B

=> S L1 AND PY<=1995
       16580008 PY<=1995
L4            2 L1 AND PY<=1995
```

10602770

```
=> S L2 AND PY<=1995
      16580008 PY<=1995
L5            2 L2 AND PY<=1995

=> S L3 AND PY<=1995
      16580008 PY<=1995
L6            2 L3 AND PY<=1995

=> S L1 AND P/DT
       4289280 P/DT
L7          194 L1 AND P/DT

=> S L1 AND PC/US
'US' IS NOT A VALID FIELD CODE
              0 PC/US
L8            0 L1 AND PC/US

=> S L1 AND US/PC
       1257695 US/PC
L9          116 L1 AND US/PC

=> S L9 AND PY<=1996
      17346007 PY<=1996
L10           0 L9 AND PY<=1996

=> S L9 AND PY<=1995
      16580008 PY<=1995
L11           0 L9 AND PY<=1995

=> d l4 ibib abs hitstr tot

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         1995:593903  CAPLUS
DOCUMENT NUMBER:          123:25342
TITLE:                    Epothilones, a new class of
                          microtubule-stabilizing agents with a taxol-like
                          mechanism of action
AUTHOR(S):                Bollag, Daniel M.; McQueney, Patricia A.; Zhu, Jian;
                          Hensens, Otto; Koupal, Lawrence; Liesch, Jerrold;
                          Goetz, Michael; Lazarides, Elias; Woods, Catherine M.
CORPORATE SOURCE:         Dep. Pharmacology, Merck Res. Laboratories, West
                          Point, PA, 19486, USA
SOURCE:                   Cancer Research (1995), 55(11), 2325-33
                          CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER:                American Association for Cancer Research
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   The antineoplastic agent taxol hyperstabilizes polymerized microtubules,
     leading to mitotic arrest and cytotoxicity in proliferating cells.  By
     using a sensitive filtration-calorimetric assay to detect microtubule
     nucleating activity, epothilones A and B were identified as
     compds. that possess all the biol. effects of taxol both in vitro and in
     cultured cells.  The 2 epothilones were equipotent and exhibited
     kinetics similar to those of taxol in inducing tubulin polymerization to
     microtubules in vitro and in producing enhanced microtubule stability and
     bundling in cultured cells.  Furthermore, these 16-membered macrolides
     were competitive inhibitors of [3H]taxol binding, exhibiting an IC50
     almost identical to that of taxol in displacement competition assays.
     Like taxol, the epothilones also caused cell cycle arrest at the
```

G2-M transition, leading to cytotoxicity. In contrast to taxol, the **epothilones** retained much greater toxicity against P-glycoprotein-expressing multiple-drug-resistant cells. **Epothilones**, therefore, represent a novel structural class of compds. which not only mimic the biol. effects of taxol but also appear to bind to the same microtubule-binding site as taxol.

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:52841 CAPLUS
DOCUMENT NUMBER: 120:52841
TITLE: **Epothilone** derivatives
INVENTOR(S): Hoefle, Gerhard; Bedorf, Norbert; Gerth, Klaus; Reichenbach, Hans
PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung mbH (GBF), Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 4138042 | A1 | 19930527 | DE 1991-4138042 | 19911119 <-- |
| DE 4138042 | C2 | 19931014 | | |
| WO 9310121 | A1 | 19930527 | WO 1992-EP2656 | 19921119 <-- |
| W: AU, CA, FI, HU, JP, KR, NO, US | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE | | | | |
| AU 9229437 | A1 | 19930615 | AU 1992-29437 | 19921119 <-- |

PRIORITY APPLN. INFO.: DE 1991-4138042 19911119
WO 1992-EP2656 19921119

OTHER SOURCE(S): MARPAT 120:52841
GI




I

AB Fungicidal antibiotic **epothilones** I (R1 = H, alkyl, acyl, Li, etc.; R2 = H, Me) and a fermentative process for their preparation are claimed. The process for their preparation comprises the fermentation of Sorangium cellulosum in the presence of a resin. During the fermentation epothilon A (R1 = R2 = H) and **epothilone** B (R1 = H, R2 = Me) are bound to the resin. Agrochem. fungicides containing **epothilone** A and **epothilone** B are claimed.

=> d l5 ibib abs hitstr tot

L5 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:593903 CAPLUS
DOCUMENT NUMBER: 123:25342
TITLE: **Epothilones**, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
AUTHOR(S): Bollag, Daniel M.; McQueney, Patricia A.; Zhu, Jian; Hensens, Otto; Koupal, Lawrence; Liesch, Jerrold; Goetz, Michael; Lazarides, Elias; Woods, Catherine M.
CORPORATE SOURCE: Dep. Pharmacology, Merck Res. Laboratories, West Point, PA, 19486, USA
SOURCE: Cancer Research (**1995**), 55(11), 2325-33
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The antineoplastic agent taxol hyperstabilizes polymerized microtubules, leading to mitotic arrest and cytotoxicity in proliferating cells. By using a sensitive filtration-calorimetric assay to detect microtubule nucleating activity, **epothilones A** and B were identified as compds. that possess all the biol. effects of taxol both in vitro and in cultured cells. The 2 **epothilones** were equipotent and exhibited kinetics similar to those of taxol in inducing tubulin polymerization to microtubules in vitro and in producing enhanced microtubule stability and bundling in cultured cells. Furthermore, these 16-membered macrolides were competitive inhibitors of [3H]taxol binding, exhibiting an IC50 almost identical to that of taxol in displacement competition assays. Like taxol, the **epothilones** also caused cell cycle arrest at the G2-M transition, leading to cytotoxicity. In contrast to taxol, the **epothilones** retained much greater toxicity against P-glycoprotein-expressing multiple-drug-resistant cells. **Epothilones**, therefore, represent a novel structural class of compds. which not only mimic the biol. effects of taxol but also appear to bind to the same microtubule-binding site as taxol.

L5 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:52841 CAPLUS
DOCUMENT NUMBER: 120:52841
TITLE: **Epothilone** derivatives
INVENTOR(S): Hoefle, Gerhard; Bedorf, Norbert; Gerth, Klaus; Reichenbach, Hans
PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung mbH (GBF), Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| DE 4138042 | A1 | 19930527 | DE 1991-4138042 | 19911119 <-- |
| DE 4138042 | C2 | 19931014 | | |
| WO 9310121 | A1 | 19930527 | WO 1992-EP2656 | 19921119 <-- |

W: AU, CA, FI, HU, JP, KR, NO, US
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE

AU 9229437 A1 19930615 AU 1992-29437 19921119 <--
PRIORITY APPLN. INFO.: DE 1991-4138042 19911119
WO 1992-EP2656 19921119

OTHER SOURCE(S): MARPAT 120:52841
GI




I

AB Fungicidal antibiotic **epothilones** I (R1 = H, alkyl, acyl, Li, etc.; R2 = H, Me) and a fermentative process for their preparation are claimed. The process for their preparation comprises the fermentation of Sorangium cellulosum in the presence of a resin. During the fermentation epothilon A (R1 = R2 = H) and **epothilone** B (R1 = H, R2 = Me) are bound to the resin. Agrochem. fungicides containing **epothilone A** and **epothilone** B are claimed.

=> d l6 ibib abs hitstr tot

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1995:593903 CAPLUS
DOCUMENT NUMBER: 123:25342
TITLE: **Epothilones**, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action
AUTHOR(S): Bollag, Daniel M.; McQueney, Patricia A.; Zhu, Jian; Hensens, Otto; Koupal, Lawrence; Liesch, Jerrold; Goetz, Michael; Lazarides, Elias; Woods, Catherine M.
CORPORATE SOURCE: Dep. Pharmacology, Merck Res. Laboratories, West Point, PA, 19486, USA
SOURCE: Cancer Research (**1995**), 55(11), 2325-33
CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The antineoplastic agent taxol hyperstabilizes polymerized microtubules, leading to mitotic arrest and cytotoxicity in proliferating cells. By using a sensitive filtration-calorimetric assay to detect microtubule nucleating activity, **epothilones** A and B were identified as compds. that possess all the biol. effects of taxol both in vitro and in cultured cells. The 2 **epothilones** were equipotent and exhibited kinetics similar to those of taxol in inducing tubulin polymerization to microtubules in vitro and in producing enhanced microtubule stability and bundling in cultured cells. Furthermore, these 16-membered macrolides were competitive inhibitors of [3H]taxol binding, exhibiting an IC50 almost identical to that of taxol in displacement competition assays. Like taxol, the **epothilones** also caused cell cycle arrest at the

G2-M transition, leading to cytotoxicity. In contrast to taxol, the **epothilones** retained much greater toxicity against P-glycoprotein-expressing multiple-drug-resistant cells. **Epothilones**, therefore, represent a novel structural class of compds. which not only mimic the biol. effects of taxol but also appear to bind to the same microtubule-binding site as taxol.

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 1994:52841 CAPLUS
DOCUMENT NUMBER: 120:52841
TITLE: **Epothilone** derivatives
INVENTOR(S): Hoefle, Gerhard; Bedorf, Norbert; Gerth, Klaus; Reichenbach, Hans
PATENT ASSIGNEE(S): Gesellschaft fuer Biotechnologische Forschung mbH (GBF), Germany
SOURCE: Ger. Offen., 10 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| DE 4138042 | A1 | 19930527 | DE 1991-4138042 | 19911119 | <-- |
| DE 4138042 | C2 | 19931014 | | | |
| WO 9310121 | A1 | 19930527 | WO 1992-EP2656 | 19921119 | <-- |
| W: AU, CA, FI, HU, JP, KR, NO, US | | | | | |
| RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE | | | | | |
| AU 9229437 | A1 | 19930615 | AU 1992-29437 | 19921119 | <-- |

PRIORITY APPLN. INFO.: DE 1991-4138042 19911119
WO 1992-EP2656 19921119

OTHER SOURCE(S): MARPAT 120:52841
GI




I

AB Fungicidal antibiotic **epothilones** I (R1 = H, alkyl, acyl, Li, etc.; R2 = H, Me) and a fermentative process for their preparation are claimed. The process for their preparation comprises the fermentation of Sorangium cellulosum in the presence of a resin. During the fermentation epothilon A (R1 = R2 = H) and **epothilone B** (R1 = H, R2 = Me) are bound to the resin. Agrochem. fungicides containing **epothilone** A and **epothilone B** are claimed.

=> d l9 ibib abs hitstr 1-10

L9 ANSWER 1 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:120619 CAPLUS
TITLE: Method for synthesizing **epothilones** and **epothilone** analogs
INVENTOR(S): White, James David; Sundermann, Kurt Frederick; Carter, Rich Garrett
PATENT ASSIGNEE(S): Oregon State University, USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 846,154.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2004030147 | A1 | 20040212 | US 2003-354694 | 20030129 <-- |
| US 2002062030 | A1 | 20020523 | US 2001-846154 | 20010430 <-- |
| US 6596875 | B2 | 20030722 | | |

PRIORITY APPLN. INFO.: US 2001-846154 A2 20010430
US 1999-118883P P 19990205
US 2000-499596 B2 20000207

AB A method for making **epothilones** and **epothilone** analogs is described, as are novel compds. made by the method. Exemplary novel compds. include those according to the formula: 1 With respect the formula, G is selected from the group consisting of 2 R 2 substituents independently are selected from the group consisting of H and lower alkyl groups; Z is selected from the group consisting of the halogens and -CN; M is selected from the group consisting of O and NR 3 ; R 3 is selected from the group consisting of H, lower alkyl, R 4 CO, R 4 OCO, and R 4 SO 2 ; R 4 is selected from the group consisting of H, lower alkyl, and aryl; T is selected from the group consisting of CH 2 , CO, HCOH and protected derivs. thereof; W is H or OR; and X and Y independently are selected from the group consisting of O, NH, S, CO, and C. Embodiments of the method provide convenient access to analogs of the **epothilones**, such as those having alternate stereochem. and those containing an ester, amide, thioester, or alkyne moieties in the macrocycle.

L9 ANSWER 2 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:100803 CAPLUS
DOCUMENT NUMBER: 140:139483
TITLE: Method for enhancing the effectiveness of therapies of hyperproliferative diseases
INVENTOR(S): Chang, Yan; Sasak, Vodek
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 14 pp., Cont.-in-part of U.S. Ser. No. 176,235.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2004023925 | A1 | 20040205 | US 2003-408723 | 20030407 <-- |

| | | | | |
|---|---|---|---|---|
| US 2003013681 | A1 | 20030116 | US 2002-176235 | 20020620 <-- |
| US 6680306 | B2 | 20040120 | | |

PRIORITY APPLN. INFO.: US 2001-299991P P 20010621
US 2002-176235 A2 20020620

AB The efficacy of conventional cancer therapies such as surgery, chemotherapy and radiation is enhanced by the use of a therapeutic material which binds to and interacts with galectins. The therapeutic material can enhance apoptosis thereby increasing the effectiveness of oncolytic agents. It can also inhibit angiogenesis thereby moderating tumor growth and/or metastasis.

L9 ANSWER 3 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:60140 CAPLUS
DOCUMENT NUMBER: 140:117391
TITLE: Formulations for reducing toxicity of anti-infective agents
INVENTOR(S): Hausheer, Frederick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 11 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2004014730 | A1 | 20040122 | US 2002-192377 | 20020710 <-- |

PRIORITY APPLN. INFO.: US 2002-192377 20020710

AB This invention provides for pharmaceutical formulations of compds. that are useful as protective agents when administered to patients also receiving anti-infective drugs, such as antimicrobials, antifungals, or antivirals. The invention also includes methods of reducing the toxicity of various anti-infective agents by administering an effective amount of the protective agent to a patient receiving one or more anti-infective agents. The compds. that are useful as protective agents have either a sulfhydryl moiety or are reducible disulfides. Sodium phosphates are dissolved in sterile injectable water to a final concentration of 0.5% water. A suitable amount of sodium deoxycholate is added and the final pH of the injectable solution is in the range 2.0-6.0. One part by weight of pure amphotericin B is added to the mixture sodium phosphates. The amphotericin B is allowed to completely dissolve at room temperature and a suitable amount of cholesteryl sulfate is added to complex the amphotericin B. Disodium 2,2'-dithiobisethanesulfonate (15 parts) are added to the above mixture This mixture is agitated until complete dissoln. occurs and this solution is sterilized via filtration through a sterile filter. This sterile solution is stored in sterile injection vials, wherein each vial contains approx. 5 mg amphotericin B and 15 g 2,2'-dithiobisethanesulfonate in the final solution

L9 ANSWER 4 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:3450 CAPLUS
DOCUMENT NUMBER: 140:99617
TITLE: Peptide conjugates with drugs as prodrugs for activation by tissue or cell-specific proteinases
INVENTOR(S): Madison, Edwin L.; Semple, Joseph Edward; Vlasuk, George P.; Kemp, Scott Jeffrey; Komandla, Mallareddy; Siev, Daniel Vanna
PATENT ASSIGNEE(S): Corvas International, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 359 pp.

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2004001801 | A1 | 20040101 | US 2002-156214 | 20020523 <-- |

PRIORITY APPLN. INFO.: US 2002-156214 20020523

AB Conjugates of peptides with drugs that are substrates of a tissue-specific proteinases that can be used to treat diseases associated with abnormal levels of the enzyme. The enzyme may be transmembrane serine proteinase, a urokinase, or an endotheliase. The conjugates are to be substrates for proteinases that may be cell- or tissue-specific. The drug moiety of the conjugate may be cytotoxic. The drug may be bound to the peptide by a labile linker that will eliminate itself after the preliminary hydrolysis.

L9 ANSWER 5 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:1007723 CAPLUS
DOCUMENT NUMBER: 140:53374
TITLE: Detection of tubulin mutations leading to paclitaxel resistance in human tumor cells
INVENTOR(S): Cabral, Fernando
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 74 pp., Cont.-in-part of U.S. Ser. No. 574,099.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003235855 | A1 | 20031225 | US 2003-439616 | 20030516 <-- |

PRIORITY APPLN. INFO.: US 1999-135047P P 19990520
US 2000-574099 A2 20000518

AB Tubulin mutations commonly associated with resistance to paclitaxel are defined, and PCR allele-specific primers capable of detecting the mutations in DNA from tumor cells are described as well as method for treating paclitaxel-resistant cells in tumors. A simple, rapid, and cost effective means for detecting paclitaxel-resistant cells in tumor biopsies from patients receiving paclitaxel therapy is disclosed. Paclitaxel resistance is associated with lower ds.p. of microtubules and dependence is associated with very low levels of polymerization Mutations were clustered in a 14
amino acid peptide (214-threonine-228-leucine) with many of the mutations affecting leucine residues in the peptide. Further, many of the substitutions required at least two nucleotide changes. Probes that can be used to detect such substitutions are described.

L9 ANSWER 6 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:1007104 CAPLUS
DOCUMENT NUMBER: 140:35931
TITLE: Methods for treatment of acute lymphocytic leukemia
INVENTOR(S): Grupp, Stephan A.; Brown, Valerie I.
PATENT ASSIGNEE(S): The Children's Hospital of Philadelphia, USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003106622 | A2 | 20031224 | WO 2003-US17552 | 20030530 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 2004039010 | A1 | 20040226 | US 2003-453056 | 20030530 <-- |

PRIORITY APPLN. INFO.: US 2002-384245P P 20020530

AB Methods for treating patients having an early B cell-derived acute lymphoblastic leukemia with rapamycin or a derivative thereof are provided. Also provided are methods for treating patients having an early B cell derived acute lymphoblastic leukemia with rapamycin or a derivative thereof in combination with an IL-7 inhibitor. Finally methods for preventing GVHD in ALL patients following a bone marrow transplant are disclosed.

L9 ANSWER 7 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:1006754 CAPLUS
DOCUMENT NUMBER: 140:35926
TITLE: Combination of **epothilone** analogs and chemotherapeutic agents for the treatment of proliferative diseases
INVENTOR(S): Voi, Maurizio; Lebwohl, David
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003105828 | A1 | 20031224 | WO 2003-US18733 | 20030612 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 2004024032 | A1 | 20040205 | US 2003-459972 | 20030612 <-- |

PRIORITY APPLN. INFO.: US 2002-388702P P 20020614
OTHER SOURCE(S): MARPAT 140:35926

AB Compns. and methods are disclosed which are useful of the treatment and prevention of proliferative diseases. The invention discloses the use of **epothilone** analogs and chemotherapeutic agents (e.g. carboplatin) for the treatment of proliferative diseases, e.g. solid tumors and refractory tumors.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:971730 CAPLUS
DOCUMENT NUMBER: 140:27844
TITLE: Preparation of tricyclic antitumor compounds as farnesyl protein transferase inhibitors
INVENTOR(S): Zhu, Hugh Y.; Njoroge, F. George; Cooper, Alan B.; Guzi, Timothy; Rane, Dinanath F.; Minor, Keith P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Santhanam, Bama; Pinto, Patrick A.; Vibulbhan, Bancha; Keertikar, Kartik M.; Alvarez, Carmen S.; Baldwin, John J.; Li, Ge; Huang, Chia-Yu; James, Ray A.; Bishop, W. Robert; Wang, James J. S.; Desai, Jagdish A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 519 pp., Cont.-in-part of U.S. Pat. Appl. 2002 198,216.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003229099 | A1 | 20031211 | US 2002-85896 | 20020227 <-- |
| US 2002198216 | A1 | 20021226 | US 2001-940811 | 20010828 <-- |
| WO 2003072549 | A1 | 20030904 | WO 2003-US5479 | 20030225 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2000-229183P P 20000830
US 2001-940811 A2 20010828
US 2002-85896 A 20020227
US 2002-325896 A 20021219

OTHER SOURCE(S): MARPAT 140:27844
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I; one of a, b, d, e = N, N:O; remaining a, b, d, e = C (wherein each C atom has an R1 or R2 bound to said carbon); or each a, b, d, e = C (wherein each C atom has an R1 or R2); R1-R4 = H, halo, CF3,

alkoxy, etc.; R5-R7, R9 = H, CF3, alkyl, aryl, etc.; R8 = H, alkoxycarbonyl, aryloxycarbonyl, alkylsulfonyl, arylsulfonyl, etc.; dotted line = single or double bond; X = N, CH; A, B = (un)substituted CH, CH2], their stereoisomers, pharmaceutically acceptable salts, solvates, and prodrugs which are useful for inhibiting farnesyl protein transferase, were prepared E.g., a multi-step synthesis of II, was given. The compds. I have an FTP IC50 in the range of 0.05 nM to 100 nM. Also disclosed are pharmaceutical compns. comprising title compds. I as well as methods of using them to treat proliferative diseases such as cancer.

L9 ANSWER 9 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:836596 CAPLUS
DOCUMENT NUMBER: 139:333137
TITLE: Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
INVENTOR(S): Cavazza, Claudio; Pisano, Claudio; Vesci, Loredana
PATENT ASSIGNEE(S): Italy
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 769,488.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003199535 | A1 | 20031023 | US 2002-292823 | 20021113 <-- |
| WO 2000006134 | A2 | 20000210 | WO 1999-IT242 | 19990727 |
| WO 2000006134 | A3 | 20000323 | | |

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

| | | | | |
|---|---|---|---|---|
| US 2001044465 | A1 | 20011122 | US 2001-769488 | 20010126 <-- |
| US 6610699 | B2 | 20030826 | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| IT 1998-IT511 | A | 19980730 |
| IT 1999-IT206 | A | 19990407 |
| WO 1999-IT242 | A1 | 19990727 |
| US 2001-769488 | A2 | 20010126 |
| IT 1998-RM511 | A | 19980730 |
| IT 1999-RM206 | A | 19990407 |

OTHER SOURCE(S): MARPAT 139:333137

AB A method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent of the family of platin compds., taxanes, **epothilone** class, vinca alkaloids is disclosed, said method comprising the administration in a coordinated manner to a subject suffering from said peripheral neuropathies, or expected to suffer from said peripheral neuropathies, an effective amount of acetyl L-carnitine or of a pharmaceutically acceptable salt thereof. In case of prevention, acetyl L-carnitine is administered to a subject, in view of the need of a treatment with an anticancer agent, immediately before or immediately after surgical removal of the tumor, but in any case before the administration of the anticancer agent. Acetyl L-carnitine can enhance

the supportive effect of physiol. NGF during chemotherapy-induced neuropathy, thus avoiding the problem of the local and general side effects of the exogenous administration of NGF which are a major problem of this neuroprotective strategy. Acetyl L-carnitine gave statistically significant protection against taxol-induced neurotoxicity in rats.

L9 ANSWER 10 OF 116 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:836572 CAPLUS
DOCUMENT NUMBER: 139:317452
TITLE: pharmaceutical compositions comprising an antiproliferation drug and a biocompatible protein for treatment of hyperplasia
INVENTOR(S): Desai, Neil P.; Soon-Shiong, Patrick
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 16 pp., Cont.-in-part of U.S. Ser. No. 446,783.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 18
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 2003199425 | A1 | 20031023 | US 2001-847945 | 20010502 <-- |
| WO 9900113 | A1 | 19990107 | WO 1998-US13272 | 19980626 |
| W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG | | | | |
| WO 2002087545 | A1 | 20021107 | WO 2002-US14118 | 20020502 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| EP 1390014 | A1 | 20040225 | EP 2002-731657 | 20020502 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |

PRIORITY APPLN. INFO.:
US 1997-51021P P 19970627
WO 1998-US13272 A 19980626
US 2000-446783 A2 20000516
US 1997-926155 A2 19970909
US 2001-847945 A1 20010502
WO 2002-US14118 W 20020502

AB In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for reducing neointimal hyperplasia associated with vascular interventional procedures. Formulations contemplated for use herein comprise proteins and at least one pharmaceutically active agent. For example, paclitaxel nanoparticles

dispersed in human albumins were found to reduce smooth muscle proliferation and migration in the in-stent arterial restenosis rabbit model.

=> LOG Y

| COST IN U.S. DOLLARS | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| FULL ESTIMATED COST | 68.15 | 68.36 |

| DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) | SINCE FILE ENTRY | TOTAL SESSION |
|---|---|---|
| CA SUBSCRIBER PRICE | -11.09 | -11.09 |

STN INTERNATIONAL LOGOFF AT 12:20:29 ON 27 FEB 2004